Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results

Biodesix (NASDAQ:BDSX) announced its quarterly earnings data on Thursday. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.56, Zacks reports. The firm had revenue of $28.76 million for the quarter, compared to analyst estimates of $26.25 million. Biodesix had a negative return on equity of 1,009.88% and a negative net margin of 39.85%.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported strong Q4 and FY‑2025 results — total revenue of $28.8M in Q4 and $88.5M for the year, Q4 revenue up 41% YoY, gross margin improved to 83%, and the company achieved its first‑ever positive Adjusted EBITDA of $0.53M.
• Commercial traction accelerated with 18,000 Nodify tests in Q4 (+23% volume growth) and expansion into primary care now representing 12% of Nodify orders (up 67% YoY) after the company broadened its sales strategy beyond pulmonology.
• Management flagged that about $1M of Q4 revenue came from collections on claims older than one year and that typical Q1 seasonality and recent weather disruptions are expected to cause a near‑term step‑down in volumes and average revenue per test.
• 2026 guidance targets $106M–$112M in revenue (midpoint ~23% growth) with continued progress toward sustained Adjusted EBITDA positivity, supported by an expanded salesforce, higher ASPs, and operational leverage.
• The pipeline shows notable partnerships (including Thermo Fisher and Bio‑Rad) and multi‑omic/AI programs (MRD, VeriStrat expansions, ESR1 test), but management does not expect new commercial launches within 12 months and key trial readouts (e.g., ALTITUDE) are likely in 2027.

Biodesix Stock Up 7.8%

Shares of NASDAQ:BDSX opened at $15.33 on Friday. The business has a fifty day simple moving average of $9.55 and a 200 day simple moving average of $8.37. The firm has a market cap of $121.97 million, a P/E ratio of -3.16 and a beta of 0.67. Biodesix has a 12-month low of $3.44 and a 12-month high of $19.13. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 41.11.

Analyst Ratings Changes

A number of analysts recently commented on the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Biodesix in a research report on Tuesday, February 17th. William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research note on Friday. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a research note on Monday, December 22nd. Finally, Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Biodesix has an average rating of “Moderate Buy” and a consensus target price of $32.50.

Insider Buying and Selling at Biodesix

In other news, CEO Scott Hutton sold 3,559 shares of the business’s stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the transaction, the chief executive officer owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. The trade was a 7.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack W. Schuler bought 82,465 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was bought at an average price of $10.96 per share, with a total value of $903,816.40. Following the completion of the transaction, the director directly owned 1,463,210 shares of the company’s stock, valued at $16,036,781.60. This represents a 5.97% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 182,465 shares of company stock valued at $2,084,616 and sold 10,999 shares valued at $116,095. 30.10% of the stock is owned by company insiders.

Institutional Trading of Biodesix

A number of institutional investors have recently made changes to their positions in BDSX. XTX Topco Ltd increased its stake in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after buying an additional 102,494 shares during the period. Millennium Management LLC bought a new stake in Biodesix in the 3rd quarter worth $113,000. Geode Capital Management LLC grew its holdings in Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the last quarter. DRW Securities LLC purchased a new position in shares of Biodesix in the fourth quarter valued at about $105,000. Finally, State Street Corp raised its stake in shares of Biodesix by 15.6% during the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after acquiring an additional 2,400 shares during the last quarter. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.